Cyril Ramaphosa & Gilead Sciences

Cyril Ramaphosa: Cyril Ramaphosa, President of South Africa, launched the rollout of Lenacapavir, calling it a 'turning point' for the country and vowing to reach 3 million South Africans with the drug.

Gilead Sciences: Gilead Sciences developed Lenacapavir and has committed to granting a voluntary manufacturing license to a South African company, which will allow for cheaper generic versions of the drug.

Cyril Ramaphosa: Cyril Ramaphosa, President of South Africa and African Union champion, warned about the serious threat the Ebola outbreak poses to the continent and emphasized the need for a coordinated response.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Cyril Ramaphosa: South African president; expressed optimism about containment and urged no travel bans.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.

Cyril Ramaphosa: Cyril Ramaphosa>>> is not mentioned in the provided articles.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.